MACK stock forecast
Our latest prediction for Merrimack Pharmaceuticals Inc's stock price was made on the July 16, 2019 when the stock price was at 5.49$.
In the short term (2weeks), MACK's stock price should outperform the market by 3.41%. During that period the price should oscillate between -6.73% and +9.98%.
In the medium term (3months), MACK's stock price should outperform the market by 2.82%. During that period the price should oscillate between -17.12% and +26.40%.
Get email alertsCreate a solid portfolio with MACK
About Merrimack Pharmaceuticals Inc
merrimack is a fully integrated biopharmaceutical company that views cancer as a complex engineering challenge. through systems biology, which brings together the fields of biology, computing and engineering, merrimack aims to decrease uncertainty in drug development and clinical validation, and move discovery efforts beyond trial and error. such an approach has the potential to make individualized treatment of patients a reality. merrimack's first commercial product, onivydetm (irinotecan liposome injection), was approved by the u.s. fda on october 22, 2015. with four additional candidates in clinical studies, several in preclinical development and multiple biomarkers designed to support patient selection, merrimack is building one of the most robust oncology pipelines in the industry. for more information, please visit merrimack's website at www.merrimack.com or connect on twitter at @merrimackpharma.
At the moment the company generates 144M USD in revenues.
On its last earning announcement, the company reported a loss of -0.18$ per share.
The book value per share is 4.67$
Three months stock forecastJuly 16, 2019
Financials
Revenue USD | Gross Margin | Operating Income | Operating Margin | Net Income | Earnings Per Share | Dividends | Payout Ratio | Shares | Book Value Per Share | Operating Cash Flow | Cap Spending | Free Cash Flow |
---|---|---|---|---|---|---|---|---|---|---|---|---|
144M | 95.20% | -3M | -72.30% | -2M | -0.18 | - | - | 13M | 4.67 | - | - | - |